Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Lara Goldstein

558 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Biotech
  • Cannabis
  • Psychedelics

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans’ Trips And More

By Lara Goldstein
April 17, 9:13 AM
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the first two…

AWKNF

Read More
3 minute read
  • Biotech
  • Cannabis
  • Psychedelics

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More

By Lara Goldstein
April 17, 8:42 AM
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA)…

AGNPF

Read More
4 minute read
  • Biotech
  • Cannabis
  • Earnings
  • News
  • Psychedelics

Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends

By Lara Goldstein
April 15, 4:13 PM
Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three…

NUMIF

Read More
2 minute read
  • Cannabis
  • Contracts
  • Global
  • Legal
  • Management
  • News
  • Psychedelics

Optimi To Supply Psilocybin For New Zealand’s Mātai Medical Research Institute

By Lara Goldstein
April 9, 3:25 PM
Canadian licensed psychedelics pharmaceutical manufacturer Optimi Health Corp. (OTCQX:OPTHF) has signed an international agreement to supply natural psilocybin…

OPTHF

Read More
2 minute read
  • Biotech
  • Cannabis
  • Management
  • Psychedelics

DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design

By Lara Goldstein
April 3, 4:45 PM
Canadian clinical-stage biotech company Algernon Pharmaceuticals (OTCQB:AGNPF) announced its plans to move forward with an intravenous (IV) formulation…

AGNPF

Read More
3 minute read
  • Biotech
  • Cannabis
  • News
  • Psychedelics

Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

By Lara Goldstein
March 30, 8:57 AM
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two…

CMND

Read More
4 minute read
  • Biotech
  • Cannabis
  • Financing
  • Legal
  • Management
  • Psychedelics

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta’s Influence

By Lara Goldstein
March 29, 12:43 PM
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have…

ATAI

Read More
4 minute read
  • Biotech
  • Cannabis
  • Earnings
  • Psychedelics

Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline

By Lara Goldstein
March 29, 9:20 AM
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full…

ATAI

Read More
3 minute read
  • Biotech
  • Cannabis
  • News
  • Psychedelics

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

By Lara Goldstein
March 28, 4:09 PM
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a…

ATAI

Read More
3 minute read
  • Biotech
  • Cannabis
  • Global
  • Legal
  • Psychedelics

PharmAla’s Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development

By Lara Goldstein
March 27, 6:56 PM
The U.S. Patent and Trademark Office (USPTO) has granted PharmAla Biotech Holdings (OTC:MDXXF) a national patent covering the…

MDXXF

Posts pagination

1 2 … 56 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service